On June 17, 2020 Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat and host investor meetings at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference being held virtually on June 23, 2020 at 9:30 a.m. ET (Press release, Replimune, JUN 17, 2020, View Source [SID1234561180]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!